The
Latest
The Latest
Resource
H.C. Wainwright & Co. Initiates Coverage on atai Life Sciences, With Buy Rating And US$40 Price Target
Video
Cybin: Video Profile
News
Levitee Labs Appoints Dr. Mohammed Mosli as Chief People Officer of Levitee Clinics and Pharmacies in Alberta, Canada
News
Clearmind Medicine Appoints Distinguished Addiction Experts Professor Wim van den Brink and Professor Gabriele Fischer to Its Scientific Advisory Board
More Articles
FEATURED
Ketamine One Launching Two Inaugural Research Studies
News
Levitee Labs Announces Agreement with Adracare, a WELL Health Company, to Support Individuals with Addiction and Mental Health Conditions
News
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
Trending
#
News
Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating Disorders
#
News
Ketamine One Signs LOI with Veteran Services USA to Open Therapy Center
#
News
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
#
News
Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities
#
News
MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers
Companies
#
Tryp Therapeutics
NEO
NASDAQ
CSE
TSXV
Private Company
#
Cybin Inc.
NEO
NASDAQ
CSE
TSXV
Private Company
#
Field Trip Health
NEO
NASDAQ
CSE
TSXV
Private Company
#
Numinus
NEO
NASDAQ
CSE
TSXV
Private Company
#
Mydecine Innovations Group
NEO
NASDAQ
CSE
TSXV
Private Company
Features
News
Levitee Labs Announces Agreement with Adracare, a WELL Health Company, to Support Individuals with Addiction and Mental Health Conditions
Resource
H.C. Wainwright & Co. Initiates Coverage on atai Life Sciences, With Buy Rating And US$40 Price Target
Video
Cybin: Video Profile
News
Ketamine One Launching Two Inaugural Research Studies
© year Psychedelic Finance